These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29607153)

  • 21. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
    Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
    Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
    Watanabe T; Okuda K; Murase T; Moriyama S; Haneda H; Kawano O; Yokota K; Sakane T; Oda R; Inagaki H; Nakanishi R
    Oncotarget; 2018 Apr; 9(29):20769-20780. PubMed ID: 29755688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.
    Nakahama K; Osawa M; Izumi M; Yoshimoto N; Sugimoto A; Nagamine H; Ogawa K; Matsumoto Y; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
    Transl Lung Cancer Res; 2022 Dec; 11(12):2438-2451. PubMed ID: 36636414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on
    Kim T; Cha YJ; Chang YS
    Tuberc Respir Dis (Seoul); 2020 Jan; 83(1):51-60. PubMed ID: 31905432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
    Bubendorf L; Conde E; Cappuzzo F; Langfort R; Schildhaus HU; Votruba J; Concha-López Á; Esteban-Rodriguez I; Feng J; Devenport J; Boyiddle C; Morris S; Trunzer K; Kerr KM
    Cancer Cytopathol; 2020 Dec; 128(12):928-938. PubMed ID: 32721105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer.
    Lee YS; Lim JH; Ryu W; Park MH; Kim L; Kim K; Kim WY; Nam HS
    Transl Lung Cancer Res; 2021 Jun; 10(6):2539-2550. PubMed ID: 34295660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability.
    Ahn S; Woo JW; Kim H; Cho EY; Kim A; Kim JY; Kim C; Lee HJ; Lee JS; Bae YK; Kwon Y; Kim WS; Park SY
    J Breast Cancer; 2021 Jun; 24(3):266-279. PubMed ID: 34128367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing.
    Matsuo T; Imai K; Nanjo H; Takashima S; Hiroshima Y; Atari M; Kuriyama S; Ishii Y; Wakamatsu Y; Sato Y; Motoyama S; Matsumura Y; Suzuki H; Nomura K; Minamiya Y
    Thorac Cancer; 2021 Apr; 12(8):1187-1194. PubMed ID: 33650770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
    Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection.
    Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Lee HS; Jeon S; Yoo TK; Park WC; Yoon CI
    Sci Rep; 2021 Oct; 11(1):19555. PubMed ID: 34599199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
    Kim H; Kwon HJ; Park SY; Park E; Chung JH
    Oncotarget; 2017 Nov; 8(58):98524-98532. PubMed ID: 29228707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
    Xu H; Lin G; Huang C; Zhu W; Miao Q; Fan X; Wu B; Zheng X; Lin X; Jiang K; Hu D; Li C
    Sci Rep; 2017 Dec; 7(1):16956. PubMed ID: 29209070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
    Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
    Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies.
    Vlajnic T; Baur F; Soysal SD; Weber WP; Piscuoglio S; Muenst S
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):726-730. PubMed ID: 36165931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
    Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
    J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.
    Kim I; Kim A; Lee CH; Lee G; Kim A; Jo EJ; Kim MH; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS
    Medicine (Baltimore); 2019 Apr; 98(14):e14972. PubMed ID: 30946323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.
    Kim B; Lee C; Kim YA; Moon KC
    Front Oncol; 2020; 10():527385. PubMed ID: 33365265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.
    Koomen BM; Vreuls W; de Boer M; de Ruiter EJ; Hoelters J; Vink A; Willems SM
    Histopathology; 2021 Oct; 79(4):480-490. PubMed ID: 33772818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.